Introduction to Multi-Omics in Colorectal Cancer

Understanding CRC gut microbiota biomarkers is crucial for early detection and patient management. Recent multi-omics research investigated the complex interplay between intestinal mucosal microorganisms and metabolic products. Specifically, the study analyzed how microbial shifts and bile acid levels correlate with the transition from benign polyps to malignant lesions. These findings provide a novel framework for diagnosing colorectal cancer (CRC) using metabolic and microbial signatures.

Microbiomics and metabolomics analyses reveal that gut microbial richness and diversity decrease as mucosal lesions become more malignant. Researchers identified significant depletion in beneficial bacteria, such as Lachnospiraceae, Faecalibacterium, and Blautia. Moreover, these microbial changes occur alongside distinct shifts in bile acid and short-chain fatty acid (SCFA) profiles. Consequently, the study highlights a clear progression of dysbiosis from benign hyperplasia to high-grade neoplasia.

The Diagnostic Potential of CRC Gut Microbiota Biomarkers

The progression from benign hyperplasia to neoplastic lesions involves specific metabolic alterations. Notably, changes in glycocholic acid, taurocholic acid, and taurodeoxycholic acid correlate strongly with shifts in mucosal bacteria. Furthermore, levels of acetate, butyrate, and isovalerate also fluctuate during this transition. Therefore, these metabolites function as integral components of CRC gut microbiota biomarkers.

Using random forest modeling and ROC analysis, the study evaluated the diagnostic accuracy of combined biomarkers. The preliminary results suggest that mucosal microorganisms and bile acids hold significant promise for non-invasive CRC screening. However, clinicians must wait for further validation in larger, multi-center cohorts to confirm these findings. Despite the need for more data, this multi-omics approach offers a deeper understanding of the host-microbiota interaction in oncology.

Conclusion and Clinical Implications

This investigation initially suggests a potential association between intestinal mucosal bacteria, bile acids, and SCFAs in colorectal cancer progression. By identifying specific microbial signatures, clinicians may eventually pinpoint high-risk individuals before malignancy develops. Additionally, focusing on the preservation of beneficial bacteria like Lachnospiraceae could offer future therapeutic avenues. Ultimately, these multi-omics clues pave the way for more precise and early diagnostic tools in gastroenterology.

Frequently Asked Questions

Which bacteria are key CRC gut microbiota biomarkers?

Studies indicate that beneficial bacteria such as Lachnospiraceae, Faecalibacterium, and Blautia significantly decrease as colorectal lesions progress toward malignancy. Their depletion serves as a potential indicator of advancing disease.

How do bile acids relate to colorectal cancer progression?

Alterations in bile acids, specifically glycocholic and taurocholic acids, correlate with changes in the gut microbiota during the shift from benign polyps to cancer. These metabolites may serve as co-biomarkers for early diagnosis.

Disclaimer: This content is for informational and educational purposes only. It does not constitute professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified healthcare provider with any questions you may have regarding a medical condition. Refer to the latest local and national guidelines for clinical practice.

References

Yu S et al. Multi-omics association investigation of the relationship between gut microbiota and the development of colorectal cancer. Eur J Med Res. 2026 Mar 03. doi: 10.1186/s40001-026-04102-8. PMID: 41776701.

Fu T et al. Paired microbiome and metabolome analyses associate bile acid changes with colorectal cancer progression. eScholarship. 2024. Available at: https://escholarship.org/uc/item/4n98z8sw.

Liu YL et al. Gut microbiota plays a key role in the development of colorectal cancer. World J Gastroenterol. 2025 Apr 14; 31(14): 1012-1025.